Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase
Key Points
Improvement in anti-inflammatory activity indicates the effectiveness of mesalamine nanocrystals in late inflammatory phases.
Key evidence shows a twofold increase in activity compared to conventional mesalamine formulations under similar conditions.
Assessment using in vitro activity benchmarks in PMA-differentiated THP-1 cell lines highlights significant pharmaceutical characterization efforts.
This approach may enable improved drug delivery, but results remain limited to in vitro models with more testing required for in vivo validation.
Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase | Synapse